PTC Therapeutics Launches Sephience for PKU with $125M in Q1 Sales and $500M Convertible Note Offering
核心洞察
PTC Therapeutics launched Sephience (sepiapterin) for phenylketonuria (搜索), generating $125 million in first-quarter 2026 product revenues with 36% sequential growth.
As of March 31, 2026, 1,244 patients worldwide were receiving Sephience therapy, with the U.S. adding approximately 140 new patient start forms per month.
The company completed a $500 million convertible note offering to support future business development and pipeline advancement.
PTC Therapeutics has launched Sephience (sepiapterin), its newly approved therapy for phenylketonuria (搜索) (PKU), with early commercial performance exceeding expectations. The drug generated $125 million in product revenues during the first quarter of 2026, representing 36% sequential growth as adoption strengthened across both U.S. and international markets. The company simultaneously completed a $500 million convertible note offering to support future business development activity.
The launch marks a pivotal moment for PTC Therapeutics, which has built a diversified global commercial portfolio across multiple rare disease indications. Sephience is now approved in the United States, Europe, Japan, and other international markets, with management expecting the therapy to be available in nearly 30 countries by the end of 2026.
Sephience Commercial Momentum
As of March 31, 2026, a total of 1,244 patients were receiving Sephience therapy worldwide. In the United States alone, the company continued to add approximately 140 new patient start forms per month, signaling robust and sustained demand. The therapy has consistently exceeded market expectations since its 2025 launch and is now positioned as PTC's primary commercial growth driver.
"Sephience's early sales, the US$500m convertible note, and the Novartis collaboration together shape how PTC Therapeutics funds and prioritises its rare disease portfolio," analysts noted, emphasizing the importance of monitoring Sephience uptake and cash deployment from the note offering.
Diversified Rare Disease Portfolio
Beyond Sephience, PTC maintains an established Duchenne muscular dystrophy (搜索) (DMD) franchise through Emflaza, approved in the United States for patients aged two years and older, and Translarna, which continues to generate meaningful revenues in select international markets for patients with nonsense mutation DMD despite ongoing regulatory challenges in Europe.
The company's gene therapy franchise includes Upstaza/Kebilidi, an approved treatment for aromatic L-amino acid decarboxylase (AADC) deficiency commercialized across Europe, the United Kingdom, and the United States. Under a licensing agreement with Ionis Pharmaceuticals (搜索), PTC holds exclusive commercialization rights for Tegsedi and Waylivra in Latin America and the Caribbean. Tegsedi is approved for hereditary transthyretin amyloidosis (搜索) with polyneuropathy, while Waylivra is approved for rare lipid disorders including familial chylomicronemia syndrome (搜索) and familial partial lipodystrophy (搜索). PTC also receives royalty revenues from Evrysdi, Roche's globally marketed spinal muscular atrophy (搜索) therapy approved in more than 100 countries.
Pipeline Progress: Votoplam and Vatiquinone
PTC's late-stage pipeline is focused on rare neurological disorders. Votoplam, an oral splicing therapy for Huntington's disease (搜索), reported positive 24-month phase II extension data in April 2026, demonstrating dose-dependent slowing of disease progression along with a favorable safety profile. These data support the ongoing global phase III INVEST-HD study led by Novartis, and the phase III study initiation triggered a $50 million milestone payment from Novartis to PTC in the second quarter of 2026.
If successful, votoplam could become the first approved oral therapy capable of modifying Huntington's disease (搜索) progression, representing a significant commercial opportunity in a disease with high unmet medical need.
Vatiquinone, another important value driver, is progressing toward a registration-enabling study in Friedreich's ataxia (搜索), with study initiation planned for the third quarter of 2026 following constructive FDA discussions.
Financial Position and Outlook
PTC Therapeutics shares have risen 17.9% year to date, compared with the industry's 6.3% growth. Over the past 60 days, earnings per share estimates for the company have improved from a loss per share of $1.40 to earnings of 78 cents per share, while EPS estimates for 2027 have risen from $1.20 to $2.11. The stock currently holds a Zacks Rank #1 (Strong Buy).
The company trades at approximately $84.51, around 10% below the analyst price target of $93.93, and is flagged as trading 54.1% below one platform's estimated fair value. However, negative shareholders' equity and recent significant insider selling have been noted as important risk markers alongside the recent price appreciation.